Core Viewpoint - China is creating a rich ecosystem for life sciences innovation, presenting more opportunities than challenges for companies like AstraZeneca [2][4] Group 1: China's Innovation Landscape - China has made significant progress in new molecular drugs, AI applications, and cell and gene therapies, attracting multinational companies to expand their R&D presence [3] - The country has established high-level research platforms and nurtured innovative talent, forming unique research advantages [3] - China is actively promoting the integration of basic research with clinical needs and participating in global scientific collaboration [3] Group 2: AstraZeneca's Commitment to China - AstraZeneca has established its sixth global strategic R&D center in Beijing, emphasizing its commitment to China's scientific innovation capabilities [4] - The global R&D team in China is responsible for 20% of AstraZeneca's overall clinical R&D tasks, with nearly 20 global clinical trial projects led by this team [4] - AstraZeneca plans to support the establishment of approximately 800 diagnostic centers across China by the end of 2025 to enhance standardized treatment levels [6] Group 3: Collaboration and Future Prospects - AstraZeneca has engaged in 15 collaborations with 14 Chinese innovative drug companies over the past two years, indicating a vibrant life sciences ecosystem in China [5] - The launch of the "AstraZeneca Global Chronic and Rare Disease R&D Postdoctoral Program" aims to foster future leaders in drug discovery [6] - AstraZeneca aims to leverage China's research capabilities to accelerate the market introduction of early-stage drugs developed by Chinese scientists [6]

摘要 ： 谁想率先代理最新一代明星产品？海尔生物医疗、横河等大牌领衔，多家创新企业携颠覆性技术惊艳亮相。众多核心产品广邀渠道合作，日程已公布，速 速报名参会吧。 特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我们的推送。 我们正身处一个生命科学爆发式创新的黄金时代。 " 十四五 " 生物经济发展规划明确打造国家生物技术战略科技力量，加快突破生物经济发 展瓶颈。近年来，在基础科学突破、产业需求牵引、国家政策支持、金融资本涌入等多重因素协同作用下，伴随 AI 、自动化与多组学技术等 深度融合，生命科学仪器创新成果密集涌现，势必为生命科学发现和生物经济发展提供核心工具支撑。 创新厂商手握颠覆性技术和产品，却苦于市场认知度低、渠道网络薄弱，难以快速触达终端用户，"酒香也怕巷子深"。优秀经销商渴望代理更 具 竞 争 力 和 利 润 空 间 的 创 新 产 品 ， 但 如 何 高 效 、 精 准 找 到 代 理 标 的 ， 成 为 阻 碍 业 务 发 展 的 难 点 、 痛 点 。 为 此 ， 仪 器 信 息 网 精 心 组 织 策 划 "2025生命科学创新仪器 ...

睿智医药波士顿研发中心 波士顿研发中心的正式启用彰显了睿智医药全球化战略的实质性推进——通过国际化的研发平台建设，深化与全球合作伙伴的技术协同，为创新药物研发注 入新动能。 波士顿研发中心：全球布局的关键落子 作为睿智医药"全球布局，本地服务"战略的重要落子，波士顿研发中心具备多重核心优势。在战略区位上，它坐落于波士顿生物科技走廊核心地带，直连全 球最顶尖的药企与科研机构，深度融入全球生命科学创新高地；全链条能力方面，覆盖从早期发现到IND申报的全链条研发服务，能够有效帮助北美客户规 避跨境物流限制，缩短研发周期，加速药物推向市场。硬件与人才上，占地13800平方英尺，配备世界一流实验设备，由资深科学家团队领衔。 睿智医药董事长兼CEO胡瑞连表示："随着行业对本地化、敏捷化研发合作需求的增长，我们在波士顿建立研发中心，正是为了突破地域限制，实现与客户 的'零距离'协作。我们期待为合作伙伴提供更高效、更个性化的服务。" 在全球生物医药产业蓬勃发展的当下，医药研发领域的创新与合作成为推动行业进步的关键力量。2025年9月，全球领先的一体化医药研发服务平台睿智医 药重资投入，迎来全球战略布局的重要里程碑——波士顿研 ...

「南北联动 共筑生命科学创新新势能」 怀柔科学城生命科学产业精准对接交流会 Huairou Science City Life Science Industry Precision Matchmaking and Exchange Conference 第三期 活动咨询 : 19944 the 2017 8 + 9 4 2 . is . . . . . . t / 40 14 活动背景 继怀柔科学城在上海的生命科学产业精准对接交 流会第二期活动成功举办后,9月18日下午,我 们即将迎来第三期活动。 作为综合性国家科学中心承载地,北京怀柔科学 城正积极打造战略性前瞻性基础研究新高地,加 快建设生态宜居创新示范区,成为引领全球科学 发现和重大前沿技术突破的新引擎,为北京建设 具有全球影响力的国际科技创新中心提供核心支 撑。通过本次交流会,企业不仅能了解怀柔科学 城的多项产业支持政策,还能获得多个国家重点 科研设施和科研平台的联合科研项目对接机会, 以及与多家创投机构的交流机会,诚邀生命科学 领域的优质企业,跟与会的领导、专家、投资人 交流企业发展需求,共谋企业发展蓝图。 are and The Basis of ...

Core Viewpoint - The HICOOL 2025 Global Entrepreneurship Competition has been launched in the Changping District, Beijing, focusing on biotechnology and health services, with over 250 high-quality projects competing in various cutting-edge fields [1][3]. Group 1: Event Overview - The competition will take place over three days, featuring projects in gene therapy, cell engineering, vaccine development, blood products, protein synthesis, microbiology, health management, digital healthcare, elderly care services, and medical beauty technology [1]. - Changping District is positioned as a key area for innovation and development, providing comprehensive industrial support and diverse development space for global entrepreneurs [3]. Group 2: Regional Development and Support - Changping District has established a full-chain innovation ecosystem from basic research to industrialization, with a focus on the pharmaceutical and health industry, and has implemented policies like the "Industrial Doubling Action Plan" to enhance its global competitiveness in life sciences [3][4]. - The district has created a "Two Valleys and One Park" innovation development pattern, which includes "Energy Valley," "Life Valley," and "Higher Education Park," and has hosted the HICOOL competition for two consecutive years [3]. Group 3: Incentives and Support Mechanisms - Changping District has set up supportive policies for HICOOL competition projects, offering matching district-level rewards for city-level awards received by winning projects [3]. - A "Talent Reception Room" has been established to provide one-on-one consulting services for participating projects, connecting them with funding support, talent introduction, industrial support, and space guarantees [4].